Approval Year
| Substance Class |
Structurally Diverse
Created
by
admin
on
Edited
Mon Mar 31 20:30:51 GMT 2025
by
admin
on
Mon Mar 31 20:30:51 GMT 2025
|
| Source Materials Class | ORGANISM |
| Source Materials Type | PROTIST |
| Source Materials State | LIVE |
| Organism Family | Plasmodiidae |
| Organism Genus | Plasmodium |
| Organism Species | falciparum |
| Author | WELCH |
| Development Stage | ASEXUAL |
| Part | whole |
| Record UNII |
536WV61NML
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
536WV61NML
Created by
admin on Mon Mar 31 20:30:52 GMT 2025 , Edited by admin on Mon Mar 31 20:30:52 GMT 2025
|
PRIMARY | |||
|
5833
Created by
admin on Mon Mar 31 20:30:52 GMT 2025 , Edited by admin on Mon Mar 31 20:30:52 GMT 2025
|
PRIMARY | |||
|
Plasmodium falciparum
Created by
admin on Mon Mar 31 20:30:52 GMT 2025 , Edited by admin on Mon Mar 31 20:30:52 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
VACCINE ANTIGEN->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM | |||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
INHIBITOR OF CD
|
||
|
INHIBITOR->TARGET ORGANISM | |||
|
|
INHIBITOR->TARGET ORGANISM |
EC50
|
||
|
INHIBITOR->TARGET ORGANISM |
Activity dependent on strain
EC50
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
DSM265 displayed maximum antimalarial effects at 3 × EC50 and above, requiring a 24- to 48-hour lag phase before parasite killing. At 1 × EC50, DSM265 parasite killing was further delayed (96-hour lag phase).
EC50
|
||
|
|
INHIBITOR->TARGET ORGANISM |
Could not achieve a single dose cure regimen.
IC50
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM | |||
|
INHIBITOR->TARGET ORGANISM |
Whole-cell blood stage activity of UCT943 against a panel of resistant P. falciparum strains to determine potential for cross-resistance compared with MMV048, chloroquine (CQ) and artesunate (AS)
IC50
|
||
|
INHIBITOR->TARGET ORGANISM |
IC50
|
||
|
INHIBITOR->TARGET ORGANISM |
Chloroquine resistant strains
IC50
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM | |||
|
|
INHIBITOR->TARGET ORGANISM |
IC50
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
In vitro Plasmodium blood-stage growth inhibition assays.
EC50
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
VACCINE ANTIGEN->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
Whole-cell blood stage activity of UCT943 against a panel of resistant P. falciparum strains to determine potential for cross-resistance compared with MMV048, chloroquine (CQ) and artesunate (AS)
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
|
INHIBITOR -> TARGET |
EC50
|
||
|
INHIBITOR->TARGET ORGANISM |
A combination of clociguanil and sulphadiazine prevented the development of parasitemia caused by P. falciparum in humans.
|
||
|
INHIBITOR->TARGET ORGANISM |
Whole-cell blood stage activity of UCT943 against a panel of resistant P. falciparum strains to determine potential for cross-resistance compared with MMV048, chloroquine (CQ) and artesunate (AS)
IC50
|
